09:25 AM EDT, 08/27/2025 (MT Newswires) -- Moleculin Biotech ( MBRX ) said Wednesday it completed a phase 1B/2 trial evaluating annamycin together with cytarabine as a treatment for subjects with acute myeloid leukemia.

The biotech company said trial data showed a median overall survival of 15 months in patients with complete remission.

Moleculin Biotech ( MBRX ) said median overall survival in the second-line efficacy population was 12 months and in the intent-to-treat group was nine months.

Moleculin said it plans to release the clinical study report in Q1 2026.

Shares of the company were down more than 3% in recent Wednesday premarket activity.